Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.66 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2577670 | 0.83 | SLC6A3 (0.65) | SLC6A3SLC6A4CYP1A2CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL2577794 | 0.82 | SLC6A3 (0.62) | SLC6A3SLC6A4CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6075209 | 0.81 | SLC6A3 (0.68) | SLC6A3SLC6A4 | |
| SCHEMBL11267858 | 0.80 | SLC6A3 (0.71) | SLC6A3SLC6A4 | |
| SCHEMBL2577789 | 0.80 | SLC6A3 (0.61) | SLC6A3SLC6A4CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1537233 | 0.80 | SLC6A3 (0.61) | SLC6A3SLC6A4CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL5022083 | 0.79 | SLC6A3 (0.65) | SLC6A3SLC6A4CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL13982744 | 0.79 | SLC6A3 (1.00) | SLC6A3SLC6A4 | |
| SCHEMBL5266643 | 0.78 | SLC6A3 (0.59) | SLC6A3SLC6A4CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL25658418 | 0.77 | ALDH1A1 (0.44) | SLC6A3CYP1A2CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153667-B2 | ATPase inhibitors; Substituted fluorene or benzenerings joined to an alkylene through a sulfone or sulfoxide linkage; without excessive toxicity, irritation, allergic response etc.; sleep dioredrs like excessive sleepiness; Parkinson's disease; Alzheimer's disease; ADD; ADHA; depression, fatigue | CEPHALON, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-7915449-B2 | Contacting the corresponding sulfur compound with complex, bas and oxidizer; oxidation; isolation | CEPHALON FRANCE (FR) | 2011-03-29 | — | — | US | disclosed |
| US-7812193-B2 | Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation | CEPHALON FRANCE (FR) | 2010-10-12 | — | — | US | disclosed |
| US-20080319227-A1 | Processes for the Preparation of Modafinil and Analogs Thereof | MALLINCKRODT LLC | 2008-12-25 | — | — | US | disclosed |
| US-20080214868-A1 | PROCESS FOR ENANTIOSELECTIVE SYNTHESIS OF SINGLE ENANTIOMERS OF MODAFINIL BY ASYMMETRIC OXIDATION | CEPHALON FRANCE (FR) | 2008-09-04 | — | — | US | disclosed |
| US-20080171896-A1 | Process for Enantioselective Synthesis of Single Enantiomers of Modafinil by Asymmetric Oxidation | CEPHALON FRANCE (FR) | 2008-07-17 | — | — | US | disclosed |
| US-7368591-B2 | Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation | CEPHALON FRANCE (FR) | 2008-05-06 | — | — | US | disclosed |
| US-20080070956-A1 | Tricyclic aromatic and bis-phenyl sulfinyl derivatives | CEPHALON, INC. (US) | 2008-03-20 | — | — | US | disclosed |
| US-7317126-B2 | Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation | CEPHALON FRANCE (FR) | 2008-01-08 | — | — | US | disclosed |
| US-7314875-B2 | Tricyclic aromatic and bis-phenyl sulfinyl derivatives | CEPHALON, INC. (US) | 2008-01-01 | — | — | US | disclosed |
| US-7186860-B2 | Process for the preparation of 2-[(diphenylmethyl) thio] acetamide | ALEMBIC LIMITED (IN) | 2007-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171896-A1 | Process for Enantioselective Synthesis of Single Enantiomers of Modafinil by Asymmetric Oxidation | MAOA, CYP2F1, MAOB | SLC6A3 561/4885SLC6A4 1149/4885CYP1A2 13/4885 |
| US-20080214868-A1 | PROCESS FOR ENANTIOSELECTIVE SYNTHESIS OF SINGLE ENANTIOMERS OF MODAFINIL BY ASYMMETRIC OXIDATION | CYP2F1, MAOA, MAOB | SLC6A3 594/4885SLC6A4 1195/4885CYP1A2 11/4885 |
| US-20080070956-A1 | Tricyclic aromatic and bis-phenyl sulfinyl derivatives | PAH, TYR, AHR | SLC6A3 1001/4885SLC6A4 179/4885CYP1A2 27/4885 |
| US-20080319227-A1 | Processes for the Preparation of Modafinil and Analogs Thereof | ADH5, ADH1A, CYP2F1 | SLC6A3 386/4885SLC6A4 1546/4885CYP1A2 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.